PMID- 31315546
OWN - NLM
STAT- MEDLINE
DCOM- 20200211
LR  - 20200211
IS  - 2578-5826 (Electronic)
IS  - 2578-5826 (Linking)
VI  - 42
IP  - 2
DP  - 2019 Jun
TI  - The effectiveness of adalimumab treatment for non-infectious uveitis.
PG  - 79-83
LID - 10.1080/25785826.2019.1642080 [doi]
AB  - Uveitis, which is a major cause of blindness worldwide, is defined as intraocular 
      inflammation that affects the iris, ciliary body, vitreous, retina and choroid. 
      Tumor necrosis factor-alpha (TNF-alpha) is a key cytokine involved in the 
      pathogenesis of many inflammatory diseases including uveitis. Corticosteroids and 
      immunosuppressive agents are the conventional therapy to treat non-infectious 
      uveitis. In cases that are resistant to these therapies, anti-TNF agents are 
      added. An anti-TNF-alpha agent, adalimumab, was recently approved for the treatment 
      of refractory non-infectious uveitis. In this review, we provide an introduction 
      to uveitis and summarize the effectiveness and safety of adalimumab in the 
      treatment of non-infectious uveitis.
FAU - Hasegawa, Eiichi
AU  - Hasegawa E
AD  - Department of Ophthalmology, Kyushu University Graduate School of Medicine , 
      Fukuoka , Japan.
FAU - Takeda, Atsunobu
AU  - Takeda A
AD  - National Hospital Organization Kyushu Medical Center , Fukuoka , Japan.
FAU - Yawata, Nobuyo
AU  - Yawata N
AD  - Department of Ophthalmology, Kyushu University Graduate School of Medicine , 
      Fukuoka , Japan.
FAU - Sonoda, Koh-Hei
AU  - Sonoda KH
AD  - Department of Ophthalmology, Kyushu University Graduate School of Medicine , 
      Fukuoka , Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190717
PL  - England
TA  - Immunol Med
JT  - Immunological medicine
JID - 101736847
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/administration & dosage/adverse effects/pharmacology/*therapeutic use
MH  - Anti-Inflammatory Agents/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Behcet Syndrome/drug therapy/etiology
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Sarcoidosis/drug therapy/etiology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - Uveitis/*drug therapy/*etiology
MH  - Uveomeningoencephalitic Syndrome/drug therapy/etiology
OTO - NOTNLM
OT  - Non-infectious uveitis
OT  - TNF-alpha
OT  - adalimumab
EDAT- 2019/07/19 06:00
MHDA- 2020/02/12 06:00
CRDT- 2019/07/19 06:00
PHST- 2019/07/19 06:00 [pubmed]
PHST- 2020/02/12 06:00 [medline]
PHST- 2019/07/19 06:00 [entrez]
AID - 10.1080/25785826.2019.1642080 [doi]
PST - ppublish
SO  - Immunol Med. 2019 Jun;42(2):79-83. doi: 10.1080/25785826.2019.1642080. Epub 2019 
      Jul 17.